Linagliptin vs Yogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Linagliptin · Tradjenta

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00602472 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.

Reported efficacy

The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)

Result source: NCT01243424

Yogliptin

Developed by Chengdu Easton Biopharmaceuticals

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05318326 · Phase 3 · status unknown

The trial randomly assigns patients to Yogliptin or a matching placebo and blinds patients, care providers, investigators and outcome assessors alike, using HbA1c change, the standard regulator-accepted measure for diabetes drugs, as its main result. Results have not been posted yet, so whether Yogliptin lowered blood sugar significantly more than placebo is not yet known.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLinagliptinYogliptin
HbA1c, change-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
—Not reported
Body weight, change (kg)1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
—Not reported
HbA1c below 7%26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
—Not reported
Fasting plasma glucose, change-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
—Not reported
3-point MACE (% with event)20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
—Not reported

HbA1c, change

Linagliptin
-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
Yogliptin
—Not reported

Body weight, change (kg)

Linagliptin
1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
Yogliptin
—Not reported

HbA1c below 7%

Linagliptin
26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
Yogliptin
—Not reported

Fasting plasma glucose, change

Linagliptin
-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
Yogliptin
—Not reported

3-point MACE (% with event)

Linagliptin
20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
Yogliptin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Yogliptin: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Linagliptin: 4 of 4 rows · Yogliptin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLinagliptin
Dropout rate
7.3%a
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
7.5%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.3%
NCT01243424 · Phase 3
0%
NCT02467478 · Phase 4 · registry result, not featured evidence
15%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
24%
NCT01897532 · Phase 4 · registry result, not featured evidence
5.3%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
20%
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
14%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
11.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
4.1%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.8%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
9.9%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
11.6%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
9.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
10.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
22.2%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
28.6%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
33.8%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
27.8%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
6.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
9%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
6.8%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
11.3%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
2.4%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
3.7%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
12.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
6.8%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.7%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
24.5%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.9%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
17%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
20.4%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
21.2%
NCT00740051 · Phase 3 · registry result, not featured evidence
5.8%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
5.4%
NCT00621140 · Phase 3 · registry result, not featured evidence
4.5%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
7.2%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.9%a
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
1.7%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—
NCT01243424 · Phase 3
—
NCT02467478 · Phase 4 · registry result, not featured evidence
—5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
10.3%
NCT01897532 · Phase 4 · registry result, not featured evidence
4%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.3%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.9%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
2.2%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
4.2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
4.8%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
3.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.9%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
4.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
3.4%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
2%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
1.5%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.7%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
1.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.4%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
4%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.8%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
4.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
2.6%
NCT00740051 · Phase 3 · registry result, not featured evidence
1.5%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT00621140 · Phase 3 · registry result, not featured evidence
1.3%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
3.6%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Serious AEs
3.2%a
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
3.4%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4%5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
46.4%
NCT01243424 · Phase 3
7.1%
NCT02467478 · Phase 4 · registry result, not featured evidence
0%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
37%
NCT01897532 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.6%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
25%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0.8%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
13%Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
15.1%Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
23.1%Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
15%
NCT02350478 · Phase 4 · registry result, not featured evidence
5.3%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.6%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
9.6%
NCT02897349 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
9.3%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
3.2%5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.5%2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
0.7%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.1%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.3%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
24.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
0.5%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
2%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.2%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
8.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.8%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.6%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.7%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0.9%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.8%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.3%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
8.6%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
0.7%
NCT00740051 · Phase 3 · registry result, not featured evidence
3.1%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00621140 · Phase 3 · registry result, not featured evidence
2.2%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
4%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
hypoglycaemia 22.7% (placebo 14.8%)
upper respiratory tract infection 5.8% (placebo 9.1%)
hyperglycaemia 5.6% (placebo 8.7%)
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 50 more results
hyperglycaemia 5.2% (placebo 14.7%)
nasopharyngitis 5.2% (placebo 5.1%)
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 20.8% (placebo 12.1%)
headache 15.6% (placebo 15.5%)
blood ketone body increased 10.4% (placebo 3.4%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
nasopharyngitis 17.5%
hypertension 14.2%
hyperglycaemia 14%
NCT01243424 · Phase 3
hypoglycaemia 29.3% (placebo 28.8%)
hypertension 6.2% (placebo 6.7%)
hyperglycaemia 6% (placebo 6.9%)
NCT01897532 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 33.8% (placebo 25.2%)
viral upper respiratory tract infection 7.3% (placebo 5.3%)
urinary tract infection 6.6% (placebo 6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 38.5% (placebo 25.2%)
viral upper respiratory tract infection 21.2% (placebo 5.3%)
bronchitis 9.6% (placebo 2.6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
infections 5.5%
renal 4.7%
surgical reintervention 4.7%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
musculoskeletal 1.1%
skin 1.1%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal 0%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
dorsal pain 5% (placebo 0%)
nausea 5% (placebo 4.3%)
toothache 5% (placebo 0%)
NCT02350478 · Phase 4 · registry result, not featured evidence
increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%)
pneumonia 5.3% (placebo 0%)
cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%)
NCT01969084 · Phase 4 · registry result, not featured evidence
5 mg
dyslipidaemia 14%
hyperglycaemia 12.7%
urinary tract infection 8.9%
NCT01512979 · Phase 4 · registry result, not featured evidence
5 mg + Metformin
dyslipidaemia 8.8%
headache 6.3%
urinary tract infection 6.3%
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
5 mg once daily + metformin once daily
diarrhoea 18%
abdominal pain 6.7%
nausea 6.7%
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 17.3% (placebo 12.7%)
upper respiratory tract infection 13.5% (placebo 12.7%)
hyperuricaemia 5.8% (placebo 1%)
NCT02897349 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 13.2% (placebo 5.6%)
nasopharyngitis 7.1% (placebo 5.6%)
upper respiratory tract infection 2.2% (placebo 5.1%)
NCT01792518 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
5 mg
diarrhoea 3%
hyperuricaemia 3%
dizziness 0%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperglycaemia 16.9%
hyperuricaemia 5.6%
nasopharyngitis 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperuricaemia 7.5%
hyperglycaemia 4.8%
upper respiratory tract infection 4.1%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD, then 2.5 mg / Metformin after week 12
hyperuricaemia 19.4%
dizziness 6.5%
hyperglycaemia 6.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg
hyperuricaemia 6.2%
hyperglycaemia 3.1%
diarrhoea 1.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 5.6%
hyperuricaemia 5.6%
upper respiratory tract infection 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 9.5%
hyperuricaemia 7.5%
upper respiratory tract infection 7.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 500 mg BID
upper respiratory tract infection 8.2%
hyperuricaemia 5.4%
diarrhoea 4.8%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
5 mg
hyperglycaemia 10.4%
nasopharyngitis 7.4%
hypertension 6.7%
NCT01183013 · Phase 3 · registry result, not featured evidence
5 mg + 15 mg / 5 mg + 30 mg
diarrhoea 7.9%
nasopharyngitis 7.1%
back pain 6.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 30 mg
oedema 9%
dizziness 6.8%
oedema peripheral 6.8%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 45 mg
oedema peripheral 11.3%
back pain 9%
urinary tract infection 5.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 59.3%
nasopharyngitis 18.6%
hyperglycaemia 17.7%
NCT01087502 · Phase 3 · registry result, not featured evidence
5 mg
hyperlipidaemia 5.5% (placebo 3%)
hyperglycaemia 2% (placebo 4%)
NCT01214239 · Phase 3 · registry result, not featured evidence
5 mg once daily
hyperglycaemia 4.9% (placebo 5%)
hyperlipidaemia 4.4% (placebo 4%)
diarrhoea 2.4% (placebo 1%)
NCT01215097 · Phase 3 · registry result, not featured evidence
5 mg tablet
anaemia 7.1% (placebo 6.7%)
hyperglycaemia 6% (placebo 7.9%)
hypoglycaemia 5.5% (placebo 4.5%)
NCT00996658 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.2%
back pain 5.9%
constipation 5.9%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 36.6%
bronchitis 11%
arthralgia 6.1%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 45.5%
pharyngitis 7.6%
constipation 4.5%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
upper respiratory tract inflammation 8.1%
arthralgia 5.4%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 31.5%
hypoglycaemia 14%
contusion 7%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 6.6% (placebo 3.3%)
hyperglycaemia 2.8% (placebo 9.2%)
NCT01194830 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 30.3% (placebo 31.3%)
hyperglycaemia 14.3% (placebo 17.8%)
nasopharyngitis 11.3% (placebo 9.8%)
NCT00954447 · Phase 3 · registry result, not featured evidence
linagliptin 2.5 mg bid + metformin 1000 mg bid
diabetes mellitus 9.9%
diarrhoea 7%
nasopharyngitis 7%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
linagliptin 2.5 mg bid + metformin 500 mg bid
hyperglycaemia 12.9%
diabetes mellitus 8%
glomerular filtration rate decreased 6.2%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 22.8% (placebo 16.5%)
nasopharyngitis 10.5% (placebo 8.9%)
diarrhoea 5.6% (placebo 2.5%)
NCT01084005 · Phase 3 · registry result, not featured evidence
hyperglycaemia 14.6%
nasopharyngitis 9.9%
dizziness 7.3%
NCT00740051 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.3% (placebo 8.5%)
upper respiratory tract infection 3.5% (placebo 7.7%)
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
hyperglycaemia 8.6% (placebo 22.8%)
NCT00621140 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 55 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Linagliptin

HbA1c 0.33% (n=52) vs NA placebo @ 26wk5 mg
absolute change · percentage points
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 129 more results
-0.53% (n=5) vs 0.15% (n=4) placebo @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.01% (n=149) vs -0.38% (n=147) placebo @ 24wk5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
-0.63% (n=161) vs -0.03% (n=156) placebo @ 24wk5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
-1.29% (n=141) vs -1.64% (n=144) Metformin @ 24wk5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
-1.34% (n=125) vs -1.68% (n=133) Metformin @ 24wk5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
-0.39% (n=130) vs -0.66% (n=124) pioglitazone @ 30wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.23% (n=130) vs -0.22% (n=124) pioglitazone @ 6wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.36% (n=130) vs -0.47% (n=124) pioglitazone @ 12wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.39% (n=130) vs -0.63% (n=124) pioglitazone @ 18wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.39% (n=130) vs -0.75% (n=124) pioglitazone @ 24wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.37% (n=130) vs -0.77% (n=124) pioglitazone @ 30wk5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.53% (n=113) vs -0.11% (n=120) placebo @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.29% (n=113) vs -0.08% (n=120) Glimepiride @ 4wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.47% (n=113) vs -0.09% (n=120) Glimepiride @ 8wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.5% (n=113) vs -0.08% (n=120) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.47% (n=113) vs -0.31% (n=120) Glimepiride @ 16wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.48% (n=113) vs -0.48% (n=120) Glimepiride @ 20wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.52% (n=113) vs -0.51% (n=120) Glimepiride @ 24wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.5% (n=113) vs -0.47% (n=120) Glimepiride @ 28wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.45% (n=113) vs -0.37% (n=120) Glimepiride @ 34wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.42% (n=113) vs -0.23% (n=120) Glimepiride @ 40wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.4% (n=113) vs -0.24% (n=120) Glimepiride @ 46wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.4% (n=113) vs -0.25% (n=120) Glimepiride @ 52wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
-0.68% (n=196) vs -0.18% (n=94) placebo @ 24wk5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
-0.454% (n=196) vs -0.072% (n=94) placebo @ 6wk5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
-0.609% (n=196) vs -0.108% (n=94) placebo @ 12wk5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
-0.67% (n=196) vs -0.159% (n=94) placebo @ 18wk5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
-0.69% (n=168) vs -0.23% (n=83) placebo @ 24wk5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
-0.66% (n=203) vs -0.14% (n=97) placebo @ 24wk5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
-0.455% (n=203) vs -0.02% (n=97) placebo @ 6wk5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
-0.653% (n=203) vs -0.062% (n=97) placebo @ 12wk5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
-0.645% (n=203) vs -0.119% (n=97) placebo @ 18wk5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
-0.68% (n=182) vs -0.16% (n=77) placebo @ 24wk5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
-0.84% (n=179) vs -0.27% (n=89) placebo @ 24wk5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
-0.6% (n=179) vs -0.19% (n=89) placebo @ 6wk5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
-0.82% (n=179) vs -0.28% (n=89) placebo @ 12wk5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
-0.91% (n=179) vs -0.37% (n=89) placebo @ 18wk5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
-0.84% (n=93) vs -0.25% (n=105) placebo @ 24wk5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
-0.64% (n=93) vs -0.22% (n=105) placebo @ 6wk5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
-0.72% (n=93) vs -0.17% (n=105) placebo @ 12wk5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
-0.81% (n=93) vs -0.26% (n=105) placebo @ 18wk5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
-0.58% (n=618) vs 0.07% (n=617) placebo @ 24wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.45% (n=618) vs 0% (n=617) placebo @ 6wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.59% (n=618) vs 0.02% (n=617) placebo @ 12wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.64% (n=618) vs 0.03% (n=617) placebo @ 18wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.56% (n=618) vs 0.01% (n=617) placebo @ 32wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.5% (n=618) vs 0.05% (n=617) placebo @ 40wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.48% (n=618) vs 0.05% (n=617) placebo @ 52wk5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
-0.61% (n=160) vs 0.04% (n=78) placebo @ 24wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
-0.42% (n=160) vs -0.07% (n=78) placebo @ 6wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
-0.6% (n=160) vs -0.03% (n=78) placebo @ 12wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
-0.58% (n=160) vs 0.04% (n=78) placebo @ 18wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
-0.52% (n=221) vs 0.28% (n=43) placebo @ 12wk5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.34% (n=221) vs 0.32% (n=43) placebo @ 6wk5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.55% (n=221) vs 0.27% (n=43) placebo @ 12wk5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.91% (n=111) vs -0.12% (n=96) placebo @ 24wk25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
-0.56% (n=110) vs 0.14% (n=106) placebo @ 24wk25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-0.94% (n=103) vs -0.12% (n=96) placebo @ 24wk10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
-0.65% (n=109) vs 0.14% (n=106) placebo @ 24wk10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-0.99% (n=298) vs -0.98% (n=341) Met @ 14wk5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
-0.28% (n=298) vs -0.25% (n=341) Met @ 2wk5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
-0.84% (n=298) vs -0.78% (n=341) Met @ 8wk5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
-0.83% (n=120) vs -0.66% (n=124) pioglitazone @ 30wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.06% (n=125) vs -0.66% (n=124) pioglitazone @ 30wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.28% (n=126) vs -0.66% (n=124) pioglitazone @ 30wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.43% (n=120) vs -0.22% (n=124) pioglitazone @ 6wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.47% (n=125) vs -0.22% (n=124) pioglitazone @ 6wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.62% (n=126) vs -0.22% (n=124) pioglitazone @ 6wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.71% (n=120) vs -0.47% (n=124) pioglitazone @ 12wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.92% (n=125) vs -0.47% (n=124) pioglitazone @ 12wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.01% (n=126) vs -0.47% (n=124) pioglitazone @ 12wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.81% (n=120) vs -0.63% (n=124) pioglitazone @ 18wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.07% (n=125) vs -0.63% (n=124) pioglitazone @ 18wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.22% (n=126) vs -0.63% (n=124) pioglitazone @ 18wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.84% (n=120) vs -0.75% (n=124) pioglitazone @ 24wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.1% (n=125) vs -0.75% (n=124) pioglitazone @ 24wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.23% (n=126) vs -0.75% (n=124) pioglitazone @ 24wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.87% (n=120) vs -0.77% (n=124) pioglitazone @ 30wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.09% (n=125) vs -0.77% (n=124) pioglitazone @ 30wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.27% (n=126) vs -0.77% (n=124) pioglitazone @ 30wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-2.15% (n=142) vs -1.64% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
-2.29% (n=141) vs -1.64% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
-2.16% (n=135) vs -1.68% (n=133) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
-2.38% (n=128) vs -1.68% (n=133) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
-0.24% (n=225) vs -0.06% (n=168) metformin @ 6wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.26% (n=171) vs -0.06% (n=168) metformin @ 6wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.29% (n=225) vs -0.08% (n=168) metformin @ 18wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.34% (n=171) vs -0.08% (n=168) metformin @ 18wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.41% (n=225) vs -0.1% (n=168) metformin @ 30wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.36% (n=171) vs -0.1% (n=168) metformin @ 30wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.35% (n=225) vs -0.14% (n=168) metformin @ 42wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.28% (n=171) vs -0.14% (n=168) metformin @ 42wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.28% (n=225) vs -0.06% (n=168) metformin @ 54wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.24% (n=171) vs -0.06% (n=168) metformin @ 54wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.34% (n=113) vs -1.19% (n=109) metformin @ 30wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.74% (n=111) vs -1.19% (n=109) metformin @ 30wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.31% (n=113) vs -1.16% (n=109) metformin @ 42wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.62% (n=111) vs -1.16% (n=109) metformin @ 42wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.41% (n=113) vs -1.2% (n=109) metformin @ 54wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.73% (n=111) vs -1.2% (n=109) metformin @ 54wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.42% (n=113) vs -1.26% (n=109) metformin @ 66wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.65% (n=111) vs -1.26% (n=109) metformin @ 66wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.32% (n=113) vs -1.25% (n=109) metformin @ 78wklinagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-1.63% (n=111) vs -1.25% (n=109) metformin @ 78wklinagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
-0.46% (n=214) vs 0.28% (n=43) placebo @ 12wk2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.34% (n=214) vs 0.32% (n=43) placebo @ 6wk2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.51% (n=214) vs 0.27% (n=43) placebo @ 12wk2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
-0.72% (n=778) vs -0.1% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.67% (n=778) vs -0.18% (n=262) placebo @ 6wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.84% (n=778) vs -0.15% (n=262) placebo @ 12wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.81% (n=778) vs -0.11% (n=262) placebo @ 18wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.49% (n=513) vs 0.15% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.363% (n=513) vs 0.069% (n=175) placebo @ 6wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.499% (n=513) vs 0.096% (n=175) placebo @ 12wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.502% (n=513) vs 0.147% (n=175) placebo @ 18wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.06% (n=2951) vs 0.15% (n=2949) Glimepiride @ 432wk
NCT01243424 · Phase 3
7.6% (n=128) vs 8% (n=122) Basal Bolus @ 12wk
NCT02004366 · Phase 4 · registry result, not featured evidence
6.6% (n=92) vs 8% (n=122) Basal Bolus @ 12wk
NCT02004366 · Phase 4 · registry result, not featured evidence
7% (n=93) vs 8% (n=122) Basal Bolus @ 12wk
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
8.6% (n=39) vs 8% (n=122) Basal Bolus @ 12wk
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
-0.61% (n=100) vs -0.2% (n=99) placebo @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
-1.06% (n=252) vs -0.56% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.41% (n=252) vs -0.03% (n=128) placebo @ 6wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.85% (n=252) vs -0.35% (n=128) placebo @ 12wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-1.06% (n=252) vs -0.55% (n=128) placebo @ 18wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.44% (n=333) vs 0.25% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
-0.37% (n=333) vs 0.09% (n=163) placebo @ 6wk
NCT00621140 · Phase 3 · registry result, not featured evidence
-0.46% (n=333) vs 0.16% (n=163) placebo @ 12wk
NCT00621140 · Phase 3 · registry result, not featured evidence
-0.45% (n=333) vs 0.21% (n=163) placebo @ 18wk
NCT00621140 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -0.83 vs -1.66 Metformin mmol/L @ 24wk5 mg QD
absolute change · mmol/L
NCT01708902 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15.03 mg/dL as posted
show 95 more results
-0.08 vs -0.84 pioglitazone mmol/L @ 30wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -1.46 mg/dL as posted
-0.24 vs -0.8 pioglitazone mmol/L @ 6wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -4.25 mg/dL as posted
-0.41 vs -0.59 pioglitazone mmol/L @ 12wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.43 mg/dL as posted
-0.39 vs -0.93 pioglitazone mmol/L @ 18wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.06 mg/dL as posted
-0.26 vs -0.9 pioglitazone mmol/L @ 24wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -4.6 mg/dL as posted
0 vs -0.98 pioglitazone mmol/L @ 30wk*5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -0.09 mg/dL as posted
0.01 vs 0.53 Glimepiride mmol/L @ 12wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from 0.24 mg/dL as posted
-0.59 vs 0.54 Glimepiride mmol/L @ 4wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.55 mg/dL as posted
-0.62 vs 0.5 Glimepiride mmol/L @ 8wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.25 mg/dL as posted
-0.35 vs 0.35 Glimepiride mmol/L @ 12wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -6.26 mg/dL as posted
-0.33 vs -0.54 Glimepiride mmol/L @ 20wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -5.92 mg/dL as posted
-0.71 vs -0.49 Glimepiride mmol/L @ 24wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12.78 mg/dL as posted
-0.52 vs -0.54 Glimepiride mmol/L @ 28wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -9.31 mg/dL as posted
-0.15 vs -0.55 Glimepiride mmol/L @ 34wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -2.78 mg/dL as posted
-0.15 vs -0.04 Glimepiride mmol/L @ 40wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -2.69 mg/dL as posted
-0.11 vs -0.15 Glimepiride mmol/L @ 46wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -2.03 mg/dL as posted
0.17 vs -0.17 Glimepiride mmol/L @ 52wk*5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence · converted to mmol/L from 3.09 mg/dL as posted
-0.67 vs -0.04 placebo mmol/L @ 6wk*5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12 mg/dL as posted
-0.61 vs -0.12 placebo mmol/L @ 12wk*5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11 mg/dL as posted
-0.58 vs -0.06 placebo mmol/L @ 18wk*5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.5 mg/dL as posted
-0.45 vs 0.08 placebo mmol/L @ 24wk*5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.1 mg/dL as posted
-0.59 vs -0.06 placebo mmol/L @ 24wk*5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.7 mg/dL as posted
-0.93 vs 0.29 placebo mmol/L @ 6wk*5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.8 mg/dL as posted
-0.82 vs -0.25 placebo mmol/L @ 12wk*5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.7 mg/dL as posted
-0.74 vs -0.11 placebo mmol/L @ 18wk*5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -13.4 mg/dL as posted
-0.57 vs 0.01 placebo mmol/L @ 24wk*5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.3 mg/dL as posted
-0.18 vs 0.69 placebo mmol/L @ 6wk*5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -3.3 mg/dL as posted
-0.39 vs 0.21 placebo mmol/L @ 12wk*5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.1 mg/dL as posted
-0.48 vs -0.13 placebo mmol/L @ 18wk*5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.6 mg/dL as posted
-1.27 vs -0.61 placebo mmol/L @ 24wk*5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.9 mg/dL as posted
-0.39 vs 0.25 placebo mmol/L @ 24wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.09 mg/dL as posted
-0.14 vs 0.03 placebo mmol/L @ 52wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -2.55 mg/dL as posted
-0.29 vs 0.16 placebo mmol/L @ 6wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -5.29 mg/dL as posted
-0.42 vs -0.02 placebo mmol/L @ 12wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.59 mg/dL as posted
-0.18 vs 0.12 placebo mmol/L @ 18wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -3.3 mg/dL as posted
-0.39 vs 0 placebo mmol/L @ 24wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.07 mg/dL as posted
-0.35 vs -0.15 placebo mmol/L @ 32wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -6.3 mg/dL as posted
-0.36 vs -0.22 placebo mmol/L @ 40wk*5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -6.5 mg/dL as posted
-0.59 vs 0.56 placebo mmol/L @ 24wk*5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.6 mg/dL as posted
-0.78 vs 0.26 placebo mmol/L @ 6wk*5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.1 mg/dL as posted
-0.82 vs 0.38 placebo mmol/L @ 12wk*5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.7 mg/dL as posted
-0.67 vs 0.53 placebo mmol/L @ 18wk*5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12 mg/dL as posted
-1.18 vs -0.19 placebo mmol/L @ 12wk*5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -21.3 mg/dL as posted
-1.75 vs 0.34 placebo mmol/L @ 24wk25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-1.46 vs 0.34 placebo mmol/L @ 24wk10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-1.36 vs -1.48 Met mmol/L @ 14wk*5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -24.5 mg/dL as posted
-1.05 vs -0.84 pioglitazone mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -18.84 mg/dL as posted
-1.52 vs -0.84 pioglitazone mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.33 mg/dL as posted
-1.95 vs -0.84 pioglitazone mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.19 mg/dL as posted
-1.07 vs -0.8 pioglitazone mmol/L @ 6wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.25 mg/dL as posted
-1.49 vs -0.8 pioglitazone mmol/L @ 6wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -26.89 mg/dL as posted
-1.57 vs -0.8 pioglitazone mmol/L @ 6wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -28.36 mg/dL as posted
-1 vs -0.59 pioglitazone mmol/L @ 12wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.99 mg/dL as posted
-1.73 vs -0.59 pioglitazone mmol/L @ 12wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.25 mg/dL as posted
-1.58 vs -0.59 pioglitazone mmol/L @ 12wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -28.53 mg/dL as posted
-1.06 vs -0.93 pioglitazone mmol/L @ 18wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.01 mg/dL as posted
-1.73 vs -0.93 pioglitazone mmol/L @ 18wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.22 mg/dL as posted
-1.7 vs -0.93 pioglitazone mmol/L @ 18wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.66 mg/dL as posted
-0.93 vs -0.9 pioglitazone mmol/L @ 24wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -16.68 mg/dL as posted
-1.75 vs -0.9 pioglitazone mmol/L @ 24wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.48 mg/dL as posted
-1.75 vs -0.9 pioglitazone mmol/L @ 24wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.49 mg/dL as posted
-1 vs -0.98 pioglitazone mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.93 mg/dL as posted
-1.5 vs -0.98 pioglitazone mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.11 mg/dL as posted
-1.89 vs -0.98 pioglitazone mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -34.04 mg/dL as posted
-2.18 vs -1.66 Metformin mmol/L @ 24wk*2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -39.33 mg/dL as posted
-2.63 vs -1.66 Metformin mmol/L @ 24wk*2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -47.44 mg/dL as posted
-0.68 vs -0.24 metformin mmol/L @ 2wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -12.22 mg/dL as posted
-0.59 vs -0.24 metformin mmol/L @ 2wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -10.57 mg/dL as posted
-0.74 vs -0.23 metformin mmol/L @ 6wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.28 mg/dL as posted
-0.75 vs -0.23 metformin mmol/L @ 6wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.46 mg/dL as posted
-0.65 vs -0.06 metformin mmol/L @ 18wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.76 mg/dL as posted
-0.71 vs -0.06 metformin mmol/L @ 18wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -12.88 mg/dL as posted
-0.75 vs -0.4 metformin mmol/L @ 30wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.49 mg/dL as posted
-0.77 vs -0.4 metformin mmol/L @ 30wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.9 mg/dL as posted
-0.53 vs -0.41 metformin mmol/L @ 42wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.46 mg/dL as posted
-0.73 vs -0.41 metformin mmol/L @ 42wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.1 mg/dL as posted
-0.4 vs -0.33 metformin mmol/L @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -7.24 mg/dL as posted
-0.55 vs -0.33 metformin mmol/L @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.82 mg/dL as posted
-0.95 vs -0.19 placebo mmol/L @ 12wk*2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17.2 mg/dL as posted
-0.26 vs 0.45 placebo mmol/L @ 24wk*
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.6 mg/dL as posted
-0.64 vs 0.35 placebo mmol/L @ 6wk*
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -11.5 mg/dL as posted
-0.53 vs 0.34 placebo mmol/L @ 12wk*
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.5 mg/dL as posted
-0.26 vs 0.41 placebo mmol/L @ 18wk*
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -4.7 mg/dL as posted
-0.59 vs 0.58 placebo mmol/L @ 24wk*
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.68 mg/dL as posted
-0.66 vs 0.25 placebo mmol/L @ 6wk*
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -11.94 mg/dL as posted
-0.71 vs 0.21 placebo mmol/L @ 12wk*
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.86 mg/dL as posted
-0.58 vs 0.57 placebo mmol/L @ 18wk*
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.51 mg/dL as posted
-1.81 vs -1.02 placebo mmol/L @ 24wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -32.6 mg/dL as posted
-1.85 vs -0.94 placebo mmol/L @ 6wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.3 mg/dL as posted
-1.88 vs -1.14 placebo mmol/L @ 12wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.8 mg/dL as posted
-1.84 vs -1.07 placebo mmol/L @ 18wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.2 mg/dL as posted
-0.47 vs 0.82 placebo mmol/L @ 24wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.47 mg/dL as posted
-0.6 vs 0.37 placebo mmol/L @ 6wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.87 mg/dL as posted
-0.6 vs 0.57 placebo mmol/L @ 12wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.75 mg/dL as posted
-0.4 vs 0.73 placebo mmol/L @ 18wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.25 mg/dL as posted
HbA1c Less Than 7 37.8% (n=149) vs 14.6% (n=147) placebo @ 24wk5 mg
absolute value · percentage points
NCT02240680 · Phase 4 · registry result, not featured evidence
show 12 more results
22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
19.4% (n=108) vs 9.1% (n=110) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
38.9% (n=149) vs 8.3% (n=72) placebo @ 24wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
41.9% (n=160) vs 11.5% (n=78) placebo @ 24wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
29.2% (n=742) vs 8.1% (n=247) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
31.2% (n=778) vs 9.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
26.2% (n=485) vs 9.2% (n=163) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3% (n=513) vs 11.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
42.9% (n=252) vs 30.5% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
42.9% (n=252) vs 30.5% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
25.2% (n=306) vs 11.6% (n=147) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
28.2% (n=333) vs 15.3% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 6 5 9.9% (n=115) vs 6.7% (n=120) Glimepiride @ 52wk5 mg
absolute value · percentage points
NCT01087502 · Phase 3 · registry result, not featured evidence
show 9 more results
6.1% (n=115) vs 5% (n=120) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
13.1% (n=777) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
13.1% (n=778) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4% (n=511) vs 2.3% (n=171) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.7% (n=513) vs 3.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
10.6% (n=329) vs 4.9% (n=162) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
10.8% (n=333) vs 4.9% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Reduction 0 5 58.2% (n=778) vs 30.2% (n=262) placebo @ 24wk
absolute value · percentage points
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
49.7% (n=513) vs 21.7% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
PPG 2h Change mg/dL -2.86 vs -1.7 pioglitazone mmol/L @ 30wk5 mg
absolute change · mmol/L
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -51.61 mg/dL as posted
show 7 more results
-2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted
-3.73 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -67.26 mg/dL as posted
-4.88 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -87.94 mg/dL as posted
-4.71 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -84.77 mg/dL as posted
-2.71 vs 1.01 placebo mmol/L @ 24wk*
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted
-1.78 vs 0 placebo mmol/L @ 24wk*
NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted
-1.86 vs 1.38 placebo mmol/L @ 24wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted
PPG Increment Over FPG mg/dL -1.72 vs 0.61 placebo mmol/L @ 24wk
absolute value · mmol/L
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -30.9 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk5 mg
responder rate · % of participants
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time to Treatment Failure 2.37 vs 2.16 placebo months5 mg
time to event · months
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to months from 72.167 days as posted
Fasting Plasma Glucose Change mg/dL 10.29 vs 15.7 placebo mg @ 26wk5 mg
absolute change · mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 4 more results
0.12 vs 15.7 placebo mg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
-11.3 vs 0.2 placebo mg @ 24wk5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.4 vs 19.7 Glimepiride mg @ 432wk
NCT01243424 · Phase 3
-5.5 vs 0.7 placebo mg @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
Weight 1.42 vs -0.04 placebo kg @ 26wk5 mg
absolute change · kg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 4 more results
2.69 vs -0.04 placebo kg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.52 vs -0.3 placebo kg @ 24wk25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-3.06 vs -0.3 placebo kg @ 24wk10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-0.44 vs -1.05 Met kg @ 14wk5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
Seated SBP 2.21 vs 1.3 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
5.16 vs 1.3 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 60 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Yogliptin's landscape